Effectiveness and safety of vonoprazan‐based regimen for Helicobacter pylori eradication: A meta‐analysis of randomized clinical trials

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

(2021) Theodore Rokkas et al.   GASTROENTEROLOGY

Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?

(2021) Soichiro Sue et al.   Gut and Liver

Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications

(2021) Evariste Tshibangu-Kabamba et al.   Nature Reviews Gastroenterology & Hepatology

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication

(2021) Ki Young Huh et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis

(2020) Satoshi Shinozaki et al.   DIGESTION

Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis

(2020) Alexander Charles Ford et al.   GUT

The Spectrum of Helicobacter-Mediated Diseases

(2020) Karen Robinson et al.   Annual Review of Pathology-Mechanisms of Disease

437 – An Open-Label, Multi-Center, Randomized, Superiority Trial of Vonoprazan Versus Esomeprazole As Part of First-Line Triple Therapy for Helicobacter Pylori Infection

(2019) Hiroyuki Tamaki et al.   GASTROENTEROLOGY

Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition

(2019) Mototsugu Kato et al.   HELICOBACTER

Efficacy of Vonoprazan for Helicobacter pylori Eradication

(2019) Shu Kiyotoki et al.   INTERNAL MEDICINE

Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection

(2018) Wen Zhong Liu et al.   HELICOBACTER

Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori

(2018) Min Li et al.   HELICOBACTER

Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori

(2018) Soichiro Sue et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

(2017) Soichiro Sue et al.   HELICOBACTER

Screening and treating Helicobacter pylori infection for gastric cancer prevention on the population level

(2017) Yi-Chia Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

(2017) Masafumi Maruyama et al.   Canadian Journal of Gastroenterology and Hepatology

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Guidelines for the diagnosis and treatment ofHelicobacter pyloriinfection in Korea, 2013 revised edition

(2014) Sang Gyun Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology